IRCCS SAN RAFFAELE ROMA SRL
🇮🇹Italy
- Country
- 🇮🇹Italy
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
368
Active:24
Completed:116
Trial Phases
5 Phases
Phase 1:6
Phase 2:27
Phase 3:14
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (126 trials with phase data)• Click on a phase to view related trials
Not Applicable
72 (57.1%)Phase 2
27 (21.4%)Phase 3
14 (11.1%)Phase 4
7 (5.6%)Phase 1
6 (4.8%)The Embryo-endometrium Multifaceted Interface: Endometrial Cavity Molecular Microbiobial and Transcriptomic Signatures in Predictinf Pregnancy Outcome in Infertile Patients Undergoing Assisted Reproduction Technology Procedures
Active, not recruiting
- Conditions
- Infertility (IVF Patients)
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 322
- Registration Number
- NCT07085585
- Locations
- 🇮🇹
OSR Innate Immunity and tissue remodeling Unit and Centro Scienze Natalità OS, Milano, Italy
This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life Based on the Treatment Received in the Group of Patients Suffering From Malignant Lesions of the Head and Neck
Not yet recruiting
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 400
- Registration Number
- NCT07066878
- Locations
- 🇮🇹
Ospedale San Raffaele, Milan, Italy
Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen
Not yet recruiting
- Conditions
- PROMs
- Interventions
- Drug: Carboplatin/Cisplatin+Pemetrexed+Pembrolizumab/Cemiplimab for 4 cycles and then maintenance with Pemetrexed+Pembrolizumab/Cemiplimab up to 2 years or disease progression or unacceptable toxicityDrug: Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 144
- Registration Number
- NCT07061379
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele, Milano, Italy
Maternal Risk, Fetal-Neonatal Brain Connectivity, and Early Neurodevelopment: A Longitudinal Observational Study
- Conditions
- PregnancyNeurodevelopmentBrain ConnectivityNeurodevelopment Outcome
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 160
- Registration Number
- NCT07059286
- Locations
- 🇮🇹
Neuroradiology Unit and CERMAC, IRCCS Ospedale San Raffaele, Milan, MI, Italy
Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection
Completed
- Conditions
- Cellular Immune ResponseAntibody ResponseSAR-CoV-2
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 127
- Registration Number
- NCT07049497
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele, Milano, Italy
- Prev
- 1
- 2
- 3
- 4
- 5
- 74
- Next
News
No news found